Nirsevimab Library
This is a collection of current resources related to Nirsevimab.
RSV Immunization Uptake Among Infants and Pregnant Persons — Wisconsin, October 1, 2023 - March 31, 2024
This short communication looks at new prevention strategies, such as the maternal RSVpreF vaccine and nirsevimab monoclonal antibody for prevention of RSV among infants. It …
Ask aRCie
RSV Prevention in Infants: Promising Products, But at What Cost?
This commentary is related to two studies on the cost-effectiveness of maternal vaccination and nirsevimab for infants for the prevention of respiratory syncytial virus (RSV). …
Respiratory Syncytial Virus Vaccine and Nirsevimab Uptake Among Pregnant People and Their Neonates
This study was conducted to describe the uptake of the prenatal RSVpreF vaccine and infant nirsevimab during the 2023-2024 RSV season. It found high uptake …
Maternal RSVpreF and Infant Nirsevimab Immunizations Uptake During Respiratory Syncytial Virus Season
This research letter looks at a study that analyzed the uptake of RSVpreF vaccination during pregnancy and nirsevimab administration to infants during the 2023 to …
Does Nirsevimab Prevent Lower Respiratory Infections Caused by Respiratory Syncytial Virus?
2024
· University of Virginia
This study examines nirsevimab, a monoclonal antibody that helps prevent respiratory syncytial virus (RSV) infections in infants. It found that one injection of nirsevimab significantly …
Rapid Review Showed That Real-World Results on How Nirsevimab Prevented Respiratory Syncytial Virus Hospitalisations Were Similar to Randomised Trials
This brief report describes a study on nirsevimab, a treatment to prevent RSV hospitalizations in infants. Real-world results from studies in Luxembourg, Spain, and the …
Effectiveness of Nirsevimab Immunoprophylaxis Against Respiratory Syncytial Virus-Related Outcomes in Hospital and Primary Care Settings: A Retrospective Cohort Study in Infants in Catalonia (Spain)
This study in Catalonia, Spain looks at the effectiveness of nirsevimab, a monoclonal antibody for RSV, in infants under 6 months old. The study shows …
Obtaining Beyfortus Through the Vaccines for Children Program
This webpage explains how birthing hospitals can acquire Beyfortus through the Vaccines for Children (VFC) program. Hospitals can get Beyfortus through direct purchase or the …
Preventing RSV in Babies: A Scientific Milestone
This 3-minute video discusses the use of nirsevimab (Beyfortus™) to protect vulnerable infants from RSV. Dr. Paul Offit explains its benefits, clinical trial results, and …
Nirsevimab (Beyfortus) Guide to Prevent Severe RSV in Infants and Toddlers
This one-page infographic provides guidance on using nirsevimab (Beyfortus) to prevent severe RSV in infants and toddlers. It addresses high-risk conditions in children, as well …